Bactiguard expands globally with oversubscribed bond

The Swedish medical technology company, Bactiguard has increased its market this past fall with China and South Korea and the expansion continues. The corporate bond that was issued to the public is now oversubscribed, as their ambition to raise between SEK 400 million and SEK 450 million was met. The reason for this is, according to Christian...

Bactiguard ventures into the South Korean market

The Swedish medtech company Bactiguard has now entered into the market of yet another country, South Korea. On December 8th, one of the company´s most important and successful products, the BIP Foley Catheter, was approved in Korea. The BIP Foley Catheter has already been used by more than 110 million patients worldwide. The potential market in...

Cobblestones fool the innate immunity

Coating the surface of an implant or a medical device with noble metals designed to have a surface-nanostructure may reduce the risk of rejection. The researchers can now explain why: the nanostructure fools the innate immune system. The results are presented in the International Journal of Nanomedicine and the project is a collaboration between...

Bactiguard at Sweden-China Infection Control Seminar

On November 22, Bactiguard participated as co-organizer in the “Sweden-China Infection Control Seminar” hosted by the Swedish Embassy and the Swedish Trade Council in Beijing. The seminar was opened by Sweden’s Ambassador to China, Mr. Lars Fredén followed by four key note speakers talking about the threat of antibiotic resistance and the...

Bactiguard in business venture with 5 000 Chinese hospitals

Bactiguard has signed an exclusive agreement with the Chinese Pharmaceutical distributor, Jian An. The amount of 40 million Swedish kronor has been paid for the exclusive rights to sell the entire line of Bactiguard´s products throughout China. At the signing of the agreement, The Jian An company placed its first order of 70 000 Bactiguard...